ALFABET bende
Abbreviations Identities Topics About
2
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
← All topics

Transgender Athletes

Biological reality clashes with gender ideology.

The debate over transgender athletes in sports is one of the most concrete test cases for the tension between gender ideology and biological reality. On one side is the principle that trans women must be treated fully as women in all areas of life. On the other side is the scientifically established fact that a biologically male body offers structural physiological advantages in most sports disciplines.

Research published in peer-reviewed journals—including the British Journal of Sports Medicine—shows that two years of hormone therapy only partially reduces the physical advantages built up during male puberty. Bone density, lung capacity, heart size, and muscle mass remain significantly higher than in biologically female athletes of comparable level.

The Status of Women’s Sports

Women’s sports exist as a separate category precisely because biologically female athletes cannot otherwise compete with biologically male athletes. By admitting biologically male individuals into this category based on gender identity, the very raison d’être of that category is undermined. Female athletes who complain about this are dismissed as transphobic—even though they are simply asserting their right to fair competition.

International sports federations have responded in varying ways. World Athletics and World Aquatics have excluded biologically male trans athletes from the women’s category following their own scientific research. Other federations apply the IOC’s hormone threshold policy, which scientists criticize as insufficient to neutralize physiological advantages.

Not a debate about hate, but a debate about fairness

This debate is not about denying the existence or dignity of trans people. It is about whether a specific policy rule in a specific context is fair to all involved. That is a legitimate question that activists wrongly dismiss as transphobia to avoid substantive debate.

What the international reevaluation shows

The issue of trans people in sports is not separate from the broader medical reevaluation. The Cass Review (2024) in the United Kingdom led to a de facto halt on puberty blockers within NHS England. SBU and Karolinska in Sweden withdrew their support for medical transition in minors outside of a research context starting in 2022. Finland (COHERE, 2020) and Norway (UKOM, 2023) followed suit. NICE (2020) classified the evidence base for puberty blockers and cross-sex hormones as “very low certainty.”

The Netherlands is lagging behind. The Dutch Protocol—once touted as an international model—is being abandoned elsewhere. The data on which it is based do not come from randomized trials, but from observational studies with cohorts that are not generalizable to the current referral population.

How the discussion is being stifled

Regarding trans issues in sports, the gender-affirming model is defended through moral pressure and scientific claims that do not hold up to scrutiny. Anyone who refers to the Cass Review or the Scandinavian shift is not given a rebuttal but is labeled transphobic. The WPATH Files (2024) showed that even within WPATH there was uncertainty regarding informed consent for minors.

Parents who come forward with concerns are dismissed as the cause of the problem. Clinicians who advocate for caution face internal complaints and public campaigns. The result: only one side of the story remains heard.

International Reconsideration

In recent years, various national health authorities have distanced themselves from the gender-affirming model for minors. The common denominator: evidence of lasting benefits is lacking, while the risks are real.

  • Cass Review (2024). Review commissioned by NHS England, conducted by Hilary Cass. Conclusion: the evidence base for puberty blockers and cross-sex hormones in minors is weak. NHS England ceased routine prescribing of puberty blockers outside of clinical trials.

  • SBU — Sweden (2022). The Swedish Agency for Health Technology Assessment (SBU) and Karolinska University Hospital stopped prescribing puberty blockers and hormones for minors outside of clinical trials. Reason: lack of evidence for effectiveness and safety.

  • NICE — United Kingdom (2020). Two NICE evidence reviews (puberty blockers and cross-sex hormones) classified the evidence base as very low certainty. None of the studies identified met modern methodological standards.

  • COHERE — Finland (2020). The Finnish Council for Choices in Health Care revised the protocol: psychotherapy as first-line treatment, medical transition for minors only in exceptional cases and within a research setting.

  • UKOM — Norway (2023). The Norwegian UKOM classified transgender care for minors as experimental; existing protocols do not meet the requirements for evidence-based care.

  • WPATH Files (2024). Internal discussions among WPATH clinicians acknowledge that informed consent with minors is problematic and that serious side effects (bone density, fertility, cognitive development) are not adequately explained.